Acute myeloid leukemia, or AML, is a type of blood cancer that starts in the bone marrow and rapidly moves to the bloodstream. It can spread to other parts of the body, including the lymph nodes, liver, and nervous system. AML, which accounts for about 1% of all cancers, could result in 11,090 deaths this year, according to the American Cancer Society.
The company we are profiling today is a late-stage clinical biopharmaceutical company developing a WT1-targeting cancer immunotherapeutic for acute myeloid leukemia - SELLAS Life Sciences Group Inc. (SLS).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com